This article is more than 5 years old. Information may no longer be current.
Triple therapy outperforms double therapy in treatment of PCV
Triple therapy comprising photodynamic therapy, intravitreal bevacizumab and sub-Tenon triamcinolone acetonide injections markedly improved vision in eyes with treatment-naïve subfoveal polypoidal choroidal vasculopathy, according to study findings.
The retrospective, comparative, interventional case series included 36 eyes of 36 patients with treatment-naïve subfoveal polypoidal choroidal vasculopathy. Seventeen patients underwent PDT combined with intravitreal Avastin (bevacizumab, Genentech), and 19 patients underwent PDT, intravitreal bevacizumab and sub-Tenon triamcinolone acetonide (STTA) injections. All patients underwent slit lamp biomicroscopy, fundus imaging, fluorescein angiography and optical coherence tomography.
The authors evaluated best corrected visual acuity and lesion type, location and choroidal neovascularization every 3 months for 36 months.
Results showed that change in visual acuity was significantly greater in the triple therapy group than in the double therapy group, according to the researchers.
Mean baseline BCVA was 0.70 in the double therapy group and 0.66 in the triple therapy group. By 36 months, mean BCVA was 0.62 in the double therapy group and 0.36 in the triple therapy group.
Visual acuity improved by 0.3 logMAR or more in five eyes in the double therapy group (29.4%) and 10 eyes in the triple therapy group (52.6%) at 36 months. Two eyes in the double therapy group and one eye in the triple therapy group had worse BCVA at 36 months.
Lesions completely disappeared in 13 eyes in the double therapy group and 16 eyes in the triple therapy group.
Six eyes (35.3%) in the double therapy group and five eyes (26.3%) in the triple therapy group underwent retreatment. The triple therapy group went significantly longer without treatment than the double therapy group, according to the researchers.
Disclosure: The authors have no relevant financial disclosures.